Myeloma Novel Drug Targets and agents
MAGNETISMM-30: A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Alexander M. Lesokhin, MD
Assistant Professor
Memorial Sloan Kettering Cancer Center, United States